Prescient Therapeutics Ltd (ASX:PTX) managing director and CEO Steven Yatomi-Clarke speaks with Proactive’s Elisha Newell about the company’s announcement of a share purchase plan (SPP), looking to raise $8 million. Yatomi-Clarke discusses using the raised funds to progress PTX’s cancer therapies as well as putting some towards general working capital and costs of the offer. He also shares the company's plan for the remainder of this year.
Prescient Therapeutics announces share purchase plan to raise $8 million
